Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Luc M. Gerland"'
Autor:
Jean-Pierre Magaud, M. Ffrench, Paul-André Bryon, Luc M. Gerland, Nathalie Baghdassarian, Patrick Ffrench, Alexandra Peiretti
Publikováno v:
European Journal of Cell Biology. 82:253-261
Summary Involvement of CDK2 in glucocorticoid-mediated S-phase lengthening was analyzed in this work. Dexamethasone (DXM) treatment of PHA-stimulated lymphocytes induced a decrease in CDK2 mRNA expression without any change in mRNA stability. This gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963f512b0f0bdeb7af80ce6653fc0c53
https://doi.org/10.1078/0171-9335-00298
https://doi.org/10.1078/0171-9335-00298
Autor:
Nathalie Klein, Wei W. Chien, Martine Ffrench, Norbert Ifrah, Fabrice Larosa, Régine Catallo, Gilles Salles, Sandrine Hayette, Agnès Chassevent, Françoise Huguet, Marie-Christine Béné, Kheira Beldjord, Adriana Plesa, Aline Schmidt, Amel Chebel, Xavier Thomas, Thibaut Leguay, Laurence Baranger, Luc M. Gerland, Hervé Dombret, Martine Escoffre-Barbe
Publikováno v:
Leukemia research. 39(4)
Adult Acute Lymphoblastic Leukemia (ALL) therapies have been improved by pediatric-like approaches. However, treatment failures and relapses are common and new markers are needed to identify patients with poor prognosis in prospective trials. The p16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::285e3f02eb86e42b9091496d674122fd
https://pubmed.ncbi.nlm.nih.gov/25675863
https://pubmed.ncbi.nlm.nih.gov/25675863
Autor:
Agnès Chassevent, Hervé Dombret, Gilles Salles, Aline Schmidt, Xavier Thomas, Fabrice Larosa, Norbert Ifrah, Luc M. Gerland, Sandrine Hayette, Wei W. Chien, PharmSciD Marie-Christine Bene, Martine Ffrench, Laurence Baranger, Régine Catallo, Adriana Plesa, Kheira Beldjord, Amel Chebel, Huguet Françoise, Thibault Leguay, Martine Escoffre-Barbe, Nathalie Klein
Publikováno v:
Blood. 122:2579-2579
Introduction The treatment of Adult Acute Lymphoblastic Leukemia (ALL) has improved by the use of pediatric-like approaches, erasing the poor prognostic impact of numerous variables. New markers are however still needed to identify poor prognosis pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::197462b475b5a50101522949e5fc116e
https://doi.org/10.1182/blood.v122.21.2579.2579
https://doi.org/10.1182/blood.v122.21.2579.2579
Autor:
Hélène Labussière, Stephane Morisset, Mauricette Michallet, Mohamad Sobh, Elodie Gadolet, Sandrine Hayette, Madeleine Etienne, Luc M. Gerland, Isabelle Tigaud, Damien Waz, Lila Gilis, Franck E. Nicolini
Publikováno v:
Blood. 116:3407-3407
Abstract 3407 It has been demonstrated that obtaining early complete cytogenetic response (CCyR) in chronic phase (CP) chronic myeloid leukemia (CML) represents a guarantee for a better long-term outcome on imatinib 400 mg/day (IM400) (D. Marin et al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6dda64b53462b8c7e599f5e2b20017
https://doi.org/10.1182/blood.v116.21.3407.3407
https://doi.org/10.1182/blood.v116.21.3407.3407
Autor:
Danielle Treille Ritouet, Arnaud Millaret, Charles Dumontet, Carlos M. Galmarini, Luc M. Gerland
Publikováno v:
Blood. 104:1445-1445
Immunophenotyping has proven to be an interesting approach in patients with myelodysplastic syndromes (MDS)(Maynadie et al., Blood. 2002 Oct 1;100(7):2349–56). Most studies in these diseases have focused on the analysis of blast cells. We chose to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b3f437c76f8a7e1d7e4b42d8f526310
https://doi.org/10.1182/blood.v104.11.1445.1445
https://doi.org/10.1182/blood.v104.11.1445.1445